Corcept Therapeutics (CORT) Share-based Compensation (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Share-based Compensation data on file, last reported at $23.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 5.56% year-over-year to $23.0 million; the trailing twelve-month figure through Mar 2026 stood at $44.0 million (down 37.0% YoY), and the FY2025 full-year result was $72.9 million, up 18.89% from the prior year.
• Share-based Compensation advanced to $23.0 million in Q1 2026, from $9.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $46.0 million in Q4 2024 to a low of $800000.0 in Q2 2024.
• A 5-year average of $10.5 million and a median of $4.2 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 81.31% in 2022 and surged 1143.17% in 2025, its largest moves.
• Tracing CORT's Share-based Compensation over 5 years: stood at $21.6 million in 2022, then slumped by 39.58% to $13.1 million in 2023, then jumped by 252.38% to $46.0 million in 2024, then slumped by 80.0% to $9.2 million in 2025, then jumped by 150.22% to $23.0 million in 2026.
• Business Quant data shows CORT's Share-based Compensation at $23.0 million in Q1 2026, $9.2 million in Q4 2025, and $4.1 million in Q3 2025.